Guidelines and statements Guidelines NICE guideline on Thyroid cancer: assessment and management: NG230 December 2022 2022 European Thyroid Association Guideline for the management of pediatric Graves’ disease The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy MHRA Levothyroxine Prescribing Guidance 2021 Consensus Guidance on Routine Practice for Differentiated Thyroid Cancer in Scotland May 2020 2018 European Thyroid Association Guideline on the Management of Graves' Hyperthyroidism Joint Statement from the Society for Endocrinology and the British Thyroid Association regarding "Association of Radioactive Iodine Treatment with Cancer Mortality in Patients with Hyperthyroidism" December 2019 This statement was published in response to an article published in JAMA Internal Medicine Association of Radioactive Iodine Treatment with Cancer Mortality in Patients with Hyperthyroidism July 2019 NICE Guideline on Thyroid Disease: assessment and management 2019 Updated RMOC Guidance - Prescribing of Liothyronine 2019 ATA Guideline for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum 2017 ATA Guidelines for Managing Thyroid Nodules and Thyroid Cancer in Children 2015 BTA Guidelines for the Management of Thyroid Cancer 2014 2014 European Thyroid Association Guidelines for the Management of Subclinical Hypothyroidism in Pregnancy and in Children Statements Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association December 2022 Liothyronine (T3): Answering patients' questions 2016 This frequently asked questions (FAQ) sheet has been produced for patients who are on treatment with Liothyronine (T3) and are concerned that they may be required to switch to thyroxine. BTA Statement on the management of primary hypothyroidism 2015 This statement has been produced to help patients make informed decisions about their treatment. There is a wealth of advice published on the internet but often it is confusing and misleading and the BTF believes that hypothyroid patients have the right to know what this information is based on and how reliable it is. This updated statement sets out the references to the research it is based on, and also a guide to the strength of the recommendations made and the quality of the evidence used. BTF FAQ for the management of primary hypothyroidism 2015 The BTF has produced a set of Questions and Answers which accompany the BTA Statement on the Management of Primary Hypothyroidism 2015 Screening for thyroid disorders in the elderly 2011 A joint statement from the British Thyroid Association and the BTF Reports Getting It Right First Time (GIRFT) report on endocrinology Further information on liothyronine We rely on donations to fund our work providing information and support for people living with thyroid disorders. Please consider making a donation or becoming a member Please donate Become a member